A Peptide Antagonist of the TLR4–MD2 Interaction (pages 645–649)
Peter F. Slivka, Mitesh Shridhar, Gui-in Lee, Deanne W. Sammond, Mark R. Hutchinson, Alexander J. Martinko, Madison M. Buchanan, Page W. Sholar, Jeffrey J. Kearney, Jacqueline A. Harrison, Linda R. Watkins and Hang Yin
Version of Record online: 30 JAN 2009 | DOI: 10.1002/cbic.200800769
Toll-like receptors are an integral part of innate immunity in the central nervous system (CNS); they orchestrate a robust defense in response to both exogenous and endogenous danger signals. Recently, toll-like receptor 4 (TLR4) has emerged as a therapeutic target for the treatment of CNS-related diseases such as sepsis and chronic pain. We herein report a chemical biology approach by using a rationally designed peptide inhibitor to disrupt the TLR4–MD2 association, thereby blocking TLR4 signaling.